Reported results
- Worldwide sales in the third quarter totaled approximately $2.98 billion, increasing 5% on both a reported and organic basis.
- On a U.S. GAAP basis, net income totaled $298 million, or $0.57 per diluted share.
- On an adjusted basis, net income in the third quarter was $0.58 per diluted share.
- Medical Products & Therapies sales for the third quarter totaled approximately $2.1 billion, increasing 6% on both a reported and organic basis.
- Healthcare Systems & Technologies sales for the third quarter totaled approximately $806 million, increasing 4% on both a reported and organic basis.
- Free cash flow was $448 million in the third quarter.
Guidance
- Reported sales growth from continuing operations: 4% to 5%
- Organic sales growth from continuing operations: 3% to 4%
- Adjusted earnings from continuing operations per diluted share: $2.05 to $2.15
Notes
Beginning in the second quarter of 2026, Baxter updated its segment reporting structure and previously reported segment results have been recast to conform to the updated reporting structure.
Price and volatility reaction
The stock moved -7.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -19.7 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 25.46 | 2026-10-28 |
| Close after release | 23.5 | 2026-10-29 |
| Realised move | -7.7% | close to close |
| 30d ATM IV change | -19.7 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
